AFNT-211 is under clinical development by Affini-T Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AFNT-211’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AFNT-211 overview
AFNT-2111 is under development for the treatment of advanced or metastatic solid tumors, non-small cell lung (NSCLC), colorectal carcinoma(CRC) and pancreatic ductal adenocarcinoma (PDAC). It is administered through parenteral route. The therapeutic candidate comprises of autologous T cells genetically engineered through lentivirus to express T cell receptors targeting cancer cells expressing mutant KRAS G12V.
Affini-T Therapeutics overview
Affini-T Therapeutics (Affini-T) is a biotechnology company that develops T-cell therapies for oncology and immunology indications. It is investigating T-cell receptors (TCR) which include KRAS G12V, KRAS G12D, Mutant P53, and MCPyV. The company offers T-cell receptors to treat solid tumors by targeting oncogenic and viral driver mutations. Its Merkel cell polyomavirus (MCPyV) is a specific T cell receptor (TCR) program for the treatment of PD-1 refractory Merkel cell carcinoma (MCC). Affini-T utilizes the TCR discovery platform to identify, characterize, and select potent and safe naturally occurring TCRs expressed on T cells. It has operations in Boston and Seattle. Affini-T is headquartered in Watertown, Massachusetts, the US.
For a complete picture of AFNT-211’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
